Nurix Therapeutics, Inc. / Fundamentals
Income statement
- Net revenue
€69.96M - Cost of goods sold
€7.03M - Gross profit
€25.36M - SG&A expenses
€39.80M - R&D expenses
€211.01M - EBITDA
-€173.65M - D&A
€10.70M - EBIT
-€184.35M - Interest expenses
€0.00 - EBT
-€165.96M - Tax expenses
€801.77K - Net income
-€166.76M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
-€32.99M - Changes in working capital
€4.98M - Operating cash flow
-€165.30M - Capex
€7.73M - Other investing cash flow
-€142.89M - Net investing cash flow
-€189.12M - Total cash dividends paid
€0.00 - Issuance of common stock
€408.32M - Debt repayment
€0.00 - Other financing cash flow
€207.36M - Net financing cash flow
€412.87M - Foreign exchange effects
€0.00 - Net change in cash
€59.22M - Cash at end of period
€72.64M - Free cash flow
-€157.57M
Balance sheet
- Cash and cash equivalents
€71.87M - Cash and short-term investments
€414.35M - Total receivables
€16.21M - Inventory
€0.00 - Other current assets
€9.00M - Total current assets
€439.55M - Property, plant & equipment
€58.84M - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€0.00 - Other non-current assets
€6.17M - Total non-current assets
€65.02M - Total assets
€504.57M - Accounts payable
€5.08M - Short-term debt
€4.47M - Other current liabilities
€31.56M - Total current liabilities
€64.50M - Long-term debt
€39.83M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€18.46M - Total non-current liabilities
€58.29M - Total liabilities
€122.78M - Common stock
€64.82K - Retained earnings
-€715.27M - Other equity
-€17.06K - Total equity
€0.00 - Total liabilities and shareholders' equity
€504.57M
Company information
- Market capitalization
€756.89M - Employees
286 - Enterprise Value
€855.63M
Company ratios
- Gross margin
-
36.2% Much better than peer group: -16,904.0% - EBITDA margin
-
-248.2% Much better than peer group: -59,918.0% - EBIT margin
-
-263.5% Much better than peer group: -62,435.1% - EBT margin
-
-237.2% Much better than peer group: -107,455.6% - Net margin
-
-238.4% Much better than peer group: -107,933.8% - ROE
-
0.0% - ROA
-
-33.1% Even with peer group: -32.0% - Asset turnover
-
13.9% Better than peer group: 5.0% - FCF margin
-
-247.3% Much better than peer group: -58,563.0% - FCF yield
-22.9% - Efficiency ratio
348.2% - Net sales per employee
-
€244.61K - Net income per employee
-
-€583.09K